David Donabedian ^Investor

David Donabedian is a seasoned CEO and executive with over 20 years of experience in business development, venture teams, and company creation. He has a proven track record of leading and launching early-stage organizations in the biotech and biopharma industries. David is a co-founder and CEO of precision medicine companies Solu Therapeutics, DEM Bio, Axial Therapeutics, and ImmuneID. He is also a founding executive of Alcyone Therapeutics and a board member of Anuncia Inc. With a background in chemistry and polymer chemistry, David is a successful investor with several exits under his belt.